Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1

Status

Terminated 2Withdrawn 1Completed 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma 142Leukemia 111Leukemia, Myeloid, Acute 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Lymphoma, Non-Hodgkin 91Multiple Myeloma 88Lymphoma, Large B-Cell, Diffuse 80Myelodysplastic Syndromes 74Lymphoma, Follicular 73Lymphoma, Mantle-Cell 72Leukemia, Lymphocytic, Chronic, B-Cell 69Burkitt Lymphoma 67Hodgkin Disease 66Lymphoma, Large-Cell, Immunoblastic 60Lymphoma, B-Cell, Marginal Zone 49Breast Neoplasms 48Neoplasms, Plasma Cell 39Leukemia, Myeloid, Accelerated Phase 34Leukemia, Myeloid, Chronic-Phase 33Recurrence 32Myeloproliferative Disorders 32Ovarian Neoplasms 31Congenital Abnormalities 30Blast Crisis 30Sarcoma 28Dendritic Cell Sarcoma, Interdigitating 28Central Nervous System Neoplasms 28Leukemia, Myelomonocytic, Chronic 27Neuroblastoma 25Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 21

Interventions

Cyclophosphamide 65Rituximab 62fludarabine 40Etoposide 25Lenalidomide 19fludarabine phosphate 17Immunotherapy, Adoptive 17Doxorubicin 17Cytarabine 17Vincristine 15Magnetic Resonance Spectroscopy 14Prednisone 13pembrolizumab 11Specimen Handling 11Dexamethasone 10CT-P10 10Melphalan 9Carmustine 9Carboplatin 9Bortezomib 9Bendamustine Hydrochloride 9obinutuzumab 8ibrutinib 8Mycophenolic Acid 8Biopsy 8Radiotherapy 7Ifosfamide 7polatuzumab vedotin 6Whole-Body Irradiation 6Methotrexate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Lymphoma, B-Cell × Filgrastim × Clear all
NCT03579927 2020-01-29

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT00482053 2018-05-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Stanford University

Phase 2 Terminated
3 enrolled 13 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT01541072 2016-11-01

PALM2

Centre Leon Berard

Phase NA Terminated
34 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT00588094 2015-12-04

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
20 enrolled 6 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡